eccb53ccf7d1ed9ffcf047ff731dee73512997f1
CCND3.md
| ... | ... | @@ -1,5 +1,7 @@ |
| 1 | 1 | # [CCND3] |
| 2 | 2 | |
| 3 | +CCND3 (Cyclin D3) is a gene that encodes a protein involved in the regulation of the cell cycle. Mutations in CCND3 are implicated in various types of B-cell lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL). |
|
| 4 | + |
|
| 3 | 5 | ## Mutation tier |
| 4 | 6 | |
| 5 | 7 | |Entity|Tier|Description | |
| ... | ... | @@ -33,7 +35,25 @@ |
| 33 | 35 | > First described in BL in 2012 by [Schmitz R](https://pubmed.ncbi.nlm.nih.gov/22885699). First described in DLBCL in 2011 by [Morin RD](https://pubmed.ncbi.nlm.nih.gov/21796119). First described in FL in 2011 by [Morin RD](https://pubmed.ncbi.nlm.nih.gov/21796119) |
| 34 | 36 | |
| 35 | 37 | |
| 36 | - ## CCND3 Hotspots |
|
| 38 | +## CCND3 Hotspots |
|
| 39 | + |
|
| 40 | +### Exon 5 Hotspot |
|
| 41 | +E283 (Glutamic Acid 283): One of the most frequently mutated sites in CCND3. Mutations at this site can result in enhanced cyclin D3 stability and increased cell cycle progression. |
|
| 42 | + |
|
| 43 | +D290 (Aspartic Acid 290): Another common mutation in exon 5. Mutations here are associated with similar functional impacts as E283, promoting uncontrolled cell proliferation. |
|
| 44 | + |
|
| 45 | +### Exon 1 and Exon 2 |
|
| 46 | +While exon 5 is the primary hotspot, mutations in exon 1 and exon 2 have also been observed, though less frequently. These mutations can affect the regulatory regions of the gene, potentially increasing levels of CCND3 by promoting stability of the protein. |
|
| 47 | + |
|
| 48 | +### Functional Impact of CCND3 Mutations |
|
| 49 | +**Cell Cycle Dysregulation:** |
|
| 50 | +CCND3, along with other cyclins, regulates the transition from the G1 phase to the S phase of the cell cycle. Mutations in CCND3 can lead to its overexpression or increased stability, resulting in accelerated cell cycle progression and uncontrolled cell division. |
|
| 51 | + |
|
| 52 | +**Increased Protein Stability:** |
|
| 53 | +Mutations at E283 and D290 often result in the increased stability of the cyclin D3 protein, preventing its degradation. This leads to sustained activation of CDK4/6 (cyclin-dependent kinases), further driving cell cycle progression. |
|
| 54 | + |
|
| 55 | +**Oncogenic Potential:** |
|
| 56 | +The dysregulation of CCND3 due to these mutations contributes to the oncogenic potential of B-cell lymphomas. By promoting continuous cell proliferation, these mutations help lymphoma cells evade normal growth control mechanisms. |
|
| 37 | 57 | |
| 38 | 58 | | Chromosome |Coordinate (hg19) | ref>alt | HGVSp | |
| 39 | 59 | | :---:| :---: | :--: | :---: | |
| ... | ... | @@ -63,3 +83,7 @@ View coding variants in ProteinPaint [hg19](https://www.bcgsc.ca/downloads/morin |
| 63 | 83 | View all variants in GenomePaint [hg19](https://www.bcgsc.ca/downloads/morinlab/GAMBL/test/genes/CCND3.html) or [hg38](https://www.bcgsc.ca/downloads/morinlab/GAMBL/test/genes/CCND3_hg38.html) |
| 64 | 84 | |
| 65 | 85 |  |
| 86 | + |
|
| 87 | +## References |
|
| 88 | + |
|
| 89 | +*Schmitz, R., et al. (2012). "Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics." Nature, 490(7418), 116-120.* |
|
| ... | ... | \ No newline at end of file |